JP2025041725A5 - - Google Patents

Info

Publication number
JP2025041725A5
JP2025041725A5 JP2024221344A JP2024221344A JP2025041725A5 JP 2025041725 A5 JP2025041725 A5 JP 2025041725A5 JP 2024221344 A JP2024221344 A JP 2024221344A JP 2024221344 A JP2024221344 A JP 2024221344A JP 2025041725 A5 JP2025041725 A5 JP 2025041725A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
pharmaceutical composition
seq
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024221344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025041725A (ja
Filing date
Publication date
Priority claimed from JP2020560106A external-priority patent/JP7608164B2/ja
Application filed filed Critical
Publication of JP2025041725A publication Critical patent/JP2025041725A/ja
Publication of JP2025041725A5 publication Critical patent/JP2025041725A5/ja
Pending legal-status Critical Current

Links

JP2024221344A 2018-12-11 2024-12-18 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ Pending JP2025041725A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018231948 2018-12-11
JP2018231948 2018-12-11
JP2020560106A JP7608164B2 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
PCT/JP2019/048171 WO2020122034A1 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020560106A Division JP7608164B2 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Publications (2)

Publication Number Publication Date
JP2025041725A JP2025041725A (ja) 2025-03-26
JP2025041725A5 true JP2025041725A5 (cg-RX-API-DMAC7.html) 2025-10-08

Family

ID=71076370

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560106A Active JP7608164B2 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
JP2024221344A Pending JP2025041725A (ja) 2018-12-11 2024-12-18 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020560106A Active JP7608164B2 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Country Status (10)

Country Link
US (1) US20220023436A1 (cg-RX-API-DMAC7.html)
EP (1) EP3909580A4 (cg-RX-API-DMAC7.html)
JP (2) JP7608164B2 (cg-RX-API-DMAC7.html)
KR (1) KR102905497B1 (cg-RX-API-DMAC7.html)
CN (1) CN113271942A (cg-RX-API-DMAC7.html)
AU (1) AU2019396895B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011119A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191641A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106248XA (cg-RX-API-DMAC7.html)
WO (1) WO2020122034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019396895B2 (en) * 2018-12-11 2025-09-11 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor
IL288485B2 (en) * 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
IL301921A (en) * 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combining an antibody-drug conjugate and a selective 1PARP inhibitor
WO2022248268A1 (en) * 2021-05-28 2022-12-01 Adc Therapeutics Sa Combination therapy
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
AU2022392822B9 (en) * 2021-11-18 2026-08-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CN116407612A (zh) * 2021-12-29 2023-07-11 上海市第十人民医院 一种药物组合物及其在制备抗肿瘤药物中的应用
CA3248038A1 (en) * 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
CN119255825A (zh) * 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
AU2024236246A1 (en) * 2023-03-14 2025-10-30 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor
JPWO2024204679A1 (cg-RX-API-DMAC7.html) * 2023-03-31 2024-10-03
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
EP4495003A1 (en) 2023-07-20 2025-01-22 AIRBUS HELICOPTERS DEUTSCHLAND GmbH An external cargo adapter for use with a rotorcraft
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026019375A1 (en) * 2024-07-19 2026-01-22 Hummingbird Bioscience Pte. Ltd. B7h3-binding molecules
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026133218A1 (en) 2024-12-20 2026-06-25 Astrazeneca Uk Limited Combination of anti-her2 antibody-drug conjugate and anti-trop2 antibody-drug conjugate
WO2026158602A1 (zh) * 2025-01-23 2026-07-30 康百达(四川)生物医药科技有限公司 Parp1抑制剂联合adc的药物组合及其治疗肿瘤的用途
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
JP6282232B2 (ja) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
SG10201902571VA (en) * 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) * 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US10195175B2 (en) * 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
SG11201906554RA (en) * 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
AU2019396895B2 (en) * 2018-12-11 2025-09-11 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor

Similar Documents

Publication Publication Date Title
JPWO2020122034A5 (cg-RX-API-DMAC7.html)
JP2023542066A5 (cg-RX-API-DMAC7.html)
JP2023539715A5 (cg-RX-API-DMAC7.html)
JP2023545096A5 (cg-RX-API-DMAC7.html)
JP7608164B2 (ja) 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
JPWO2020031936A5 (cg-RX-API-DMAC7.html)
JP2023070678A5 (cg-RX-API-DMAC7.html)
TWI865337B (zh) 抗體-藥物結合物之有效的製造方法
JP2020515578A5 (cg-RX-API-DMAC7.html)
JPWO2020130125A5 (cg-RX-API-DMAC7.html)
JP2022095908A5 (cg-RX-API-DMAC7.html)
JP2024075668A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2020019787A5 (cg-RX-API-DMAC7.html)
JP2019031565A5 (cg-RX-API-DMAC7.html)
JP2023531252A5 (cg-RX-API-DMAC7.html)
JP2024546605A5 (cg-RX-API-DMAC7.html)
JPWO2022102695A5 (cg-RX-API-DMAC7.html)
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2024501894A5 (cg-RX-API-DMAC7.html)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2020500834A5 (cg-RX-API-DMAC7.html)
JPWO2019230645A5 (cg-RX-API-DMAC7.html)
JPWO2022102634A5 (cg-RX-API-DMAC7.html)
JP2025509266A5 (cg-RX-API-DMAC7.html)
JPWO2020040245A5 (cg-RX-API-DMAC7.html)